Kineta Immuno-Oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference
Tags:
Oncology
Immunotherapy
Immuno-Oncology
New data on Kineta's small molecule RIG-I agonists in tumor models to be unveiled
SEATTLE, March 22, 2018 /PRNewswire/ -- Kineta Immuno-Oncology, LLC, a biotechnology company focused on developing disruptive technologies to turn cold tumors hot, today announced that they have been invited to present at the Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations. Dr. Peter Probst, Kineta Immuno-oncology Head of Immunology, will present a poster on Kineta's RIG-I Immuno-Oncology program. The conference takes place on March 23-27 at the Fairmont, The Queen Elizabeth Hotel in Montreal, Canada.
Dr. Probst will present new data on Kineta Immuno-Oncology's RIG-I agonists demonstrating significant reduction in tumor growth in two mouse tumor models; CT26 colon carcinoma and B16F10 melanoma. Additionally, a newly identified RIG-I lead candidate with potent innate immune activation and immunogenic cell death activities showing orthogonal confirmation around the lead series will be shown.
Dr. Probst will be presenting scientific poster #3016 entitled "Small molecule RIG-I agonists induce innate immune responses, immogenic tumor cell death and in vivo protective immune responses in a colon carcinoma model" on March 26th between 7:30-10pm.
Kineta, Immuno-Oncology is a privately held biotech company focused on developing disruptive technologies that shift the paradigm in cancer treatment by turning cold tumors hot. Our research and development is centered around small molecule innate immune activators of the RIG-I pathway. This novel pathway has been largely unexploited for drug discovery. Activating innate immune pathways can cause direct tumor killing and an anti-tumor immune response. Kineta Immuno-Oncology was established in 2016. Our novel technology was originally discovered through the innate immune screening platform developed by Kineta, Inc. For more information, please visit our website at www.kinetaimmuno-oncology.com.
Keystone Symposia on Molecular and Cellular Biology (www.keystonesymposia.org) is a 501(c)(3) nonprofit organization headquartered in Silverthorne, Colorado, USA that convenes open, peer-reviewed conferences across a broad range of the life sciences. Scientific content for each conference is organized by volunteer scientists who are experts in their respective fields and who also select program speakers, with guidelines from Keystone Symposia to encourage fresh and diverse participation. The conference Cancer Immunotherapy: Combinations (www.keystonesymposia.org/18C5) will specifically cover the most critical topics regarding how patients with cancer will receive immunotherapy as part of their treatment regimen. This meeting is also aimed to help address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical.
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta Immuno-Oncology's plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta Immuno-Oncology's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta Immuno-Oncology undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Contact Jacques Bouchy[email protected](206) 378-0400
SOURCE Kineta Immuno-Oncology, LLC
http://www.kinetaimmuno-oncology.com
Cision Distribution 888-776-0942
from 8 AM - 9 PM ET
